This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

DONALD SCHETMAN, MD; GEORGE W. HAMBRICK, JR., MD; CHARLES E. WILSON, MD

Arch Dermatol. 1963;88(6):820-828.

Abstract
Injection of triamcinolone diacetate at a high intradermal site results in persistent scarring secondary to local vesiculation and ulceration. Histologically, early changes included necrosis of the epidermis, the small blood vessels, and the appendages; late changes included thinning of the epidermis, loss of rete peg formation, and vascular and collagen proliferation.

Injection at a low intradermal site resulted in atrophy, pigmentary changes, and telangiectasia appearing as early as 14 days and lasting as long as ten months, depending on anatomical site. In the skin of the arms and back these changes occurred on the average at one month, lasting usually six months. In the skin of a calf these began as late as two months, lasting eight months or more. In skin of the scalp, these occurred at three weeks, lasting only three months. The histopathological changes consisted primarily of a decrease in mucopolysaccharide, which was associated with loss of elastic tissue, homogenization of collagen, epidermal atrophy, and degenerative changes in the appendages. These changes were reversible.

Injection at a high subcutaneous site usually resulted in no cutaneous change clinically. A few sites developed mild transient reversible changes both histologically and clinically similar to those seen with low intradermal injections.

No differences due to race were detected in this study. Likewise, differences attributable to age were not conclusive.

The development of triamcinolone-induced atrophy is dependent upon the anatomical level of the injection within the skin as well as the local concentrations achieved. Consideration of depth of injection and of concentration should minimize the degree of atrophy resulting.

Author Affiliations
PHILADELPHIA

From the Department of Dermatology, School of Medicine, University of Pennsylvania.

Footnotes
This study was conducted under the sponsorship of the Commission on Cutaneous Disease of the Armed Forces Epidemiological Board and was supported by the Surgeon General, Department of the Army.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Injectable Corticosteroid and Local Anesthetic Preparations: A Review for Radiologists
MacMahon et al.
Radiology 2009;252:647-661.
ABSTRACT | FULL TEXT  

Yellow Nodule Within an Atrophic Thigh Patch
Spencer et al.
Arch Dermatol 1994;130:1059-1060.
ABSTRACT  

Perilymphatic Atrophy of the Skin: A Side Effect of Topical Corticosteroid Injection Therapy
Kikuchi and Horikawa
Arch Dermatol 1974;109:558-559.
ABSTRACT  

Intralesional Steroids in Laryngeal Stenosis: A Preliminary Report
Cobb and Sudderth
Arch Otolaryngol Head Neck Surg 1972;96:52-56.
ABSTRACT  

Deep Atrophy of the Skin of the Deltoid Area
Fritsch
Arch Dermatol 1970;101:585-587.
ABSTRACT  

Pyoderma Gangrenosum: A Patient Successfully Treated With Intralesional Injections of Steroid
MOSCHELLA
Arch Dermatol 1967;95:121-123.
ABSTRACT  

Treatment of Keloids With Triamcinolone Acetonide Injected Intralesionally
Maguire
JAMA 1965;192:325-326.
ABSTRACT  

REPLY TO CRITICISM OF TRIAMCINOLONE THERAPY
Pariser and Murray
Arch Dermatol 1964;90:133-134.
ABSTRACT